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Abstract
This report is based on the Federation of American Societies for Experimental Biology’s symposium, “Engaging basic
Scientists in Translational Research: Identifying Opportunities, Overcoming Obstacles,” held in Chevy Chase, MD,
March 24–25, 2011. Meeting participants examined the benefits of engaging basic scientists in translational
research, the challenges to their participation in translational research, and the roles that research institutions,
funding organizations, professional societies, and scientific publishers can play to address these challenges.
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Engaging basic scientists in translational research:
identifying opportunities, overcoming obstacles
Basic scientists are the foundation of the biomedical re-
search enterprise [1]. Their work is key to understanding
fundamental biological processes and mechanisms of
disease pathogenesis, and it has been critical to prevent-
ing, diagnosing, and treating diseases and conditions
that afflict millions of people. Yet despite major
advances in fundamental biology, there is widespread
concern about the slow pace at which these discoveries
are translated into safe and effective clinical interven-
tions. The National Institutes of Health (NIH) estimates
that 80 percent to 90 percent of potential therapeutics in
preclinical testing run into problems that preclude them
from advancing to the clinical trial phase.a Numerous
initiatives to speed translation are under way at the na-
tional and institutional levels, many of which have been
aimed at providing clinical scientists with the knowledge
and tools needed to translate research discoveries into
improved patient care. Less attention, however, has been
given to the contributions that basic scientists make to
the process of translational research.
A somewhat fluid and amorphous concept, transla-
tional research is the term used to describe a spectrum
of scientific investigation aimed at: 1) transferring la-
boratory discoveries about disease mechanisms into new
methods for diagnosing, preventing, and treating disease
and testing these methods in humans; 2) taking results
from clinical studies into clinical practice and under-
standing the efficacy and dissemination of health care
interventions; and 3) using the knowledge gained to im-
prove health care policy. Scientists from many disci-
plines often are involved in this work, ranging from the
most basic investigators in the life, chemical, physical,
mathematical, engineering, and computer sciences to
those in the clinic. Research across the continuum does
not always proceed linearly. Often it is an iterative, bidir-
ectional process in which insights into biological
mechanisms and disease processes inform and spur new
clinical interventions and, conversely, observations about
the nature and progression of disease made in the course
of patient care and clinical research stimulate new basic
investigations. This paper focuses on the former
pathway.
Although individuals trained in basic science can con-
tribute to research at any point along this spectrum,
their expertise is especially valuable during the first, or
“T1,” stage. This is where an understanding of human
biology, pathogenesis, and basic science methods con-
verge to bear on the identification and characterization
of disease targets, assay development, lead identification
and high-throughput screening, and preclinical
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evaluation of potentially therapeutic compounds in mo-
lecular, cellular, and animal models. Recent research
breakthroughs provide an ever-widening landscape of
opportunities for basic investigators to work in these
areas. These include the completion of the Human Gen-
ome Project and dramatic advances in information tech-
nology; biocomputing; high-throughput technologies for
screening, identifying, and studying compounds of inter-
est; and novel imaging capabilities. Recognizing these
opportunities, funding agencies such as NIH have insti-
tuted an array of translational research programs (Add-
itional file 1: Table S1).
However, a number of obstacles—scientific, institu-
tional, cultural, and policy—have limited the opportun-
ities for basic investigators to conduct translational
science. This work is best conducted through multi- and
interdisciplinary collaborations, which can be difficult to
establish and maintain in the current research environ-
ment—one that encourages specialization and rewards
individual achievement and hypothesis-driven research.
In addition, basic investigators may face inadequate
funding, resources, or infrastructure for developing
translational research programs. Furthermore, they often
lack sufficient experience with essential methods and
techniques, as well as with complex regulatory require-
ments, to be effective in this realm. These challenges
can limit professional interest in the field and hamper
the translational enterprise.
To address these issues, the Federation of American
Societies for Experimental Biology (FASEB) held a sym-
posium March 24–25, 2011, that brought together basic
and clinical research trainees and scientists, department
heads, and senior leaders from diverse academic re-
search institutions; the leadership of private and public
research funding organizations, pharmaceutical research
organizations, and scientific societies; and scientific pub-
lishers. (For the agenda and a full list of registrants, see
Additional file 2 and Additional file 3.) Meeting partici-
pants explored the benefits of engaging basic scientists
in translational research, the obstacles that stand in their
way, and the roles that research institutions, funders,
professional societies, and scientific publishers can play
to help basic scientists overcome these obstacles.
The meeting was hosted by the Howard Hughes Med-
ical Institute (HHMI) in Chevy Chase, Maryland, and
was co-sponsored by the Burroughs Wellcome Fund, the
U.S. Department of Veterans Affairs, the Doris Duke
Charitable Foundation, and Merck Sharp & Dohme
Corp. All five organizations have a long track record of
supporting fundamental science and an interest in ad-
vancing human health and the treatment of disease. To
supplement information provided in the presentations,
FASEB conducted a survey of meeting participants and
nearly 2,000 FASEB society scientists. This report
describes the major survey results (see Additional file 4),
summarizes the proceedings of the meeting, and offers a
practical set of recommendations for engaging basic
scientists in translational research. FASEB’s goal is to
foster the creation of an environment that encourages
basic scientists to consider the translational potential of
their work and to pursue opportunities to apply their
knowledge and expertise to investigations directly rele-
vant to improving human health and treating disease.
The benefits of engaging in translational research
The ultimate goal of translational biomedical research is
to improve human health—an outcome that benefits all
of society. But participating in translational science also
has more direct and immediate rewards for individual
investigators and the institutions that support their
work. Three teams of panelists—paired as basic scien-
tists and senior leaders from the same university—dis-
cussed these benefits from their respective vantage
points.
Benefits to scientists
The opportunity to conduct research that has an impact
on human health is a significant factor in many scien-
tists’ decisions to participate in translational research.
Nearly three-quarters of the respondents to FASEB’s sur-
vey indicated that they initially embarked on transla-
tional work because they wanted to have an impact on a
particular disease or condition, and more than half
wanted to have an impact on human health in general.
This sentiment was echoed by Dirk Schnappinger, PhD,
Associate Professor, Weill Cornell Medical College, who
is working to validate new targets for the discovery of
drugs to treat tuberculosis. He noted that he and his
team, which includes collaborators from 13 institutions
around the world, “are motivated by having an impact
on global health and can attract people who share that
desire.” Likewise, for Michael Dyer, PhD, an HHMI Early
Career Scientist and a basic biologist studying retinal de-
velopment at St. Jude Children’s Research Hospital, the
realization that the tens of thousands of papers on the
genetics of retinoblastoma had not yet affected the way
patients with the disease are treated “fundamentally
changed the direction of [his] career and the research
direction of [his] lab” (see Table 1).
Thomas Tuschl, PhD, Associate Professor and Head of
the Laboratory for RNA Molecular Biology at The Rock-
efeller University, also wanted to apply his science to the
study of disease; partnering with clinicians helped him
to do that. Trained as a basic scientist, he obtained his
doctoral degree in chemistry, conducted postdoctoral
work in biochemistry, and then became interested in the
therapeutic applications for gene silencing through the
discovery of sRNAs and microRNAs as regulators of
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gene expression. His current work is focused on defining
the molecular pathology leading to specific diseases and
developing targeted approaches suitable for therapeutic
interventions.
Tuschl had developed an appreciation for translational sci-
ence and its challenges while working with the pharmaceut-
ical industry. As a cofounder and scientific advisor to
Alnylam Pharmaceuticals and Regulus Therapeutics, he
learned a great deal about genetic diseases, the molecular
causes underlying disease, and validation of drug targets, and
he started to look for translational research opportunities
that were within reach of his academic laboratory. His com-
mitment to the field increased when a group of highly moti-
vated Clinical Scholars joined his laboratory. These clinicians
were attracted to his work primarily because of its specialized
methods for characterizing small regulatory RNAs and their
targets, but their projects rapidly expanded and touched on
many aspects of gene regulation. He had not anticipated the
strong interest that the clinical investigators would have in
basic science and new methodologies, and he found that
pairing each clinician with a basic investigator resulted in a
considerable amount of synergy between the two.
Without the expertise that the clinicians brought to
his laboratory, Tuschl says he might have never under-
stood how to operate and devise experiments relevant to
translational medicine. By working with human tissue
samples, observing the variation among individuals and
in sample collection, following the clinicians’ progress at
the bench, and accessing their data, he learned how to
adapt his methods to study hundreds of patient and control
samples. In return, the scholars have found it helpful to
train with a basic scientist, which offered them a completely
new strategy for understanding biological phenomena.
For basic biologists, engaging in translational research
has benefits that go beyond contributing to understand-
ing and treating human disease. It helped Leslie Vos-
shall, PhD, Robin Chemers Neustein Professor and Head
of the Laboratory of Neurogenetics and Behavior at The
Rockefeller University, to learn more about her field.
Trained as a basic biomedical researcher, Vosshall used
insects to study smell for many years before turning to
people where, she said, “all the interesting action is.”
Today, she studies how humans discriminate among
smells, how genetic variation in humans alters how they
Table 1 Making a Difference: Taking the Challenges of the Clinic Back to the Laboratory
When Michael Dyer, PhD, first arrived at St. Jude as a junior faculty
member nine years ago, he was the head of a basic developmental
neurobiology research laboratory. One day, while deciding how to set
up his laboratory space, there was a knock at his door. Two clinicians
who treat retinoblastoma patients asked him to spend some time with
them in the clinic. He realized that after spending five years at a major
medical center and studying normal eye development and genetic
mutations of the eye, he had never once met a clinician, patient, or
patient’s family. He eagerly accepted the opportunity.
Dyer knew that Rb gene mutations cause retinoblastoma, a rare
childhood cancer with only 300 cases per year in the United States. But
when he asked the clinicians if the tens of thousands of papers available
on PubMed on the Rb gene and pathway had any impact on how
patients are treated, they replied that they had no impact whatsoever.
This surprising response led him to change the direction of his career
and the research direction of his laboratory.
To Dyer, the reason these basic research papers had not been
translated into new therapies was obvious: there was a lack of good
animal models for this disease. Researchers had tried to develop a
retinoblastoma model by deleting the Rb gene from the mouse
genome, but the manipulation did not cause the mouse to develop
retinoblastoma. Unbeknownst to them at the time, another protein,
p107, is able to compensate for Rb in the mouse. When both Rb and
p107 are deleted from the mouse genome, retinoblastoma develops in
about 50 percent of the animals. Using this model, he was able to test
different therapeutics against the disease. In doing so, Dyer applied
what he learned from his clinical colleagues about the actual course of
treatment in patients (i.e., clinical reality) and tested combinations of
broad-spectrum systemic 45 chemotherapeutics in a similar manner in
his mice. After going through eight different combinations of drugs
and comparing them to the current standard of care, Dyer and his
colleagues found a combination that seemed to be better than what
children currently were receiving. St. Jude started a new five-year
clinical trial based on those data. Although going from nothing to a
new clinical trial in about 18 months was satisfying, Dyer hoped to do
better.
He wanted to develop a more targeted chemotherapy that could be
delivered locally to the eye and result in fewer side effects.
Searching for a drug target, Dyer’s team discovered that patients with
retinoblastoma have increased levels of MDMX, which sequesters p53, a
tumor suppressor, and leads to cell proliferation and tumor development.
MDMX is amplified in 65 percent of patients and epigenetically turned on
in the rest.
Now having a target to go after, Dyer and colleagues developed a model
in which the MDMX gene was conditionally over expressed in the mice
that develop retinoblastoma. This resulted in a much more aggressive
disease in these animals—providing a new model to test
chemotherapeutics. Not wanting to rely solely on a genetic model, they
also developed a “xenographic” mouse model in which human tumor cells
are transplanted to an eye of an immunocompromised mouse. This results
in virtually 100 percent engraftment with tumors expressing high levels of
MDMX. Collaborations with his chemical biology colleagues, who were
able to synthesize an MDMX inhibitor, and clinicians, who provided
medical information and tumor specimens, enabled Dyer to begin a
preclinical trial focused on inhibiting MDMX.
Dyer believes that the process by which basic investigators can translate
their discoveries into clinical applications could be emulated at most major
medical or academic research centers. The building blocks important for
driving translation, such as strong basic science departments, animal
research facilities, pharmacology and pathology departments, and clinical
trial support are already in place. He also noted that some translational
work can be done with relatively few resources if one acts creatively. He
received no support from St. Jude to fund these studies directly. Rather,
Dyer built on a one-year pilot grant of $50,000 and cobbled the rest
together through other sources.
The challenge, he said, is changing the culture. Emphasizing the value of
translational research to both basic and clinical scientists, encouraging
communications between basic and clinical scientists, mentoring, and
understanding the clinical reality of disease progression and therapeutic
interventions are all important for increasing participation in translational
research and ultimately improving human health.
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perceive odors, and how mosquitoes react to our smell.
Her laboratory is one of the biggest users of the Rocke-
feller outpatient clinic and has run upwards of 1,500
volunteers through these olfaction studies.
Pursuing translational research also had benefits for
Daniel Wagner, PhD, Assistant Professor, Department of
Biochemistry and Cell Biology at Rice University. A basic
developmental biologist working in zebrafish, Wagner
embarked on a collaborative project with a physicist after
encountering him reading one of Wagner’s posters in the
hallway. The physicist was working on a theranostic
(therapeutic-diagnostic) application for plasmonic nano-
bubbles, in which gold particles are excited by short laser
pulses to generate transient vapor bubbles. The biologist
and the physicist joined up to test the concept that these
nanobubbles could be used to identify cells based on their
expression of specific cell surface molecules and to destroy
specific cells in a zebrafish. The team used these nanobub-
bles targeted to the EGF receptor and was able to destroy
prostate cancer cells within a host embryo. This was the
first step—proof of principle—that the theranostic method
can be used in vivo as a potential diagnostic tool and ul-
timately for targeted therapy.
“As I saw the group that was being assembled around
this plasmonic nanobubble project, I really began to think
that there were some serious benefits for me, as a basic
scientist, and the potential to move this technology for-
ward and ultimately translate it into the clinic,” said
Wagner. Among the benefits he cited were participation
in a quickly moving multi-investigator project that pro-
duced novel results; exposure to new fields and methods
leading to new projects; and rapid publication rate. Indeed,
Wagner noted that three papers were generated from the
nanobubble project in the year preceding the meeting,
equal to the output of all of his other projects combined.
In sum, participation in translational research benefits
basic scientists by:
 Enabling them to contribute to the understanding of
human health and disease and to participate in the
development of solutions to medical and public
health problems, which can be a source of
intellectual inspiration and stimulation.
 Providing opportunities to develop their own science
and learn new methods, which can lead to new
projects, fresh directions for existing projects, and
faster publication rates.
 Promoting collaborations with clinicians, clinical
researchers, and basic investigators in other
disciplines, which can ignite shared passion, provide
exposure to new areas of science, and generate new
ideas.
 Providing opportunities to mentor clinical colleagues
in basic science methods.
Benefits to institutions
Institutions also benefit from creating an environment
conductive to translational science. Their efforts help
their scientists by facilitating access to resources that
they may not have had before and connecting them to
collaborators with whom they share research interests,
but otherwise may not have met. These synergies move
research forward, benefitting the individual and his or
her institution. For example, at The Rockefeller Univer-
sity, Vosshall noted that in order to carry out her studies
on the sense of smell, she increasingly has to rely on the
resources that are funded by Rockefeller’s CTSA. Sup-
port for statistical work comes from its biostatisticians,
and its facilitation office has helped shepherd protocols
from initial conceptualization to final approval. She has
had to lean heavily on the clinical staffing in the out-
patient clinic, and the Institutional Review Board (IRB)
has helped improve the quality of her protocols. Work-
ing with Rockefeller’s hospital, she was able to obtain ac-
cess to the darkened space that she needed for her own
research by acquiring repurposed rooms that had been
used for sleep studies. Her work would not have been
possible without these resources.
A focus on translational research also benefits trainees
and early career scientists. It provides important training
opportunities for graduate students and postdoctorates
and may help to attract new talent into biomedical re-
search. Cindy Farach-Carson, PhD, Vice Provost for
Translational BioScience, Rice University, noted that
translational research appeals to today’s generation of
university students—many of whom want to work on
“big, real world problems.”
Farach-Carson also emphasized that establishing the
infrastructure to conduct translational research provides
opportunities for all of an institution’s investigators—not
just those working on bench-to-bedside projects. The
collaboration necessary for conducting this kind of work
involves sharing expensive equipment, forming equip-
ment cores, and developing policies for sharing, which
can work to everyone’s advantage. For example, Rice’s $9
million supercomputer from IBM came with the condi-
tion that it be shared in an affordable way with the Texas
Medical Center and others outside the center.
In addition to benefiting their scholars, investing in
translational research has a positive impact on institu-
tions as a whole. Fostering an environment conducive to
translation advances the core missions of biomedical re-
search institutions, stated Barry Coller, MD, Vice Presi-
dent for Medical Affairs and Physician-in-Chief, The
Rockefeller University Medical Center. Successes in the
development of new drugs, devices, and procedures attract
patients who want to benefit from cutting-edge care, and
they attract funding from donors with an interest in sup-
porting promising work that could lead to new treatments.
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Scott Weir, PharmD, PhD, Director, Institute for Ad-
vancing Medical Innovation, University of Kansas Can-
cer Center, described the evolution of the extensive
network of partners that formed around efforts to estab-
lish a center of excellence for cancer at his institution.
Establishing a National Cancer Institute-designated can-
cer center became a university, state, and regional prior-
ity. The center’s goal was to capitalize on the strengths
of the university and on regional assets to become a na-
tional leader in the discovery and advancement to Phase
I of promising anticancer agents.
Before the center was started, the University of Kansas
had one of the top schools of pharmacy in the United
States and strong leadership in medicinal and pharma-
ceutical chemistry. It also had conducted research that
led to the commercialization of several drug products.
But none of those products had been tested in patients
at the university’s medical center, which is located 42
miles away from the School of Pharmacy. Additionally,
its cancer biology program was in its infancy and did
not have a rich, potential source of novel cancer drug
targets. To achieve its goal of becoming one of the top
university-based cancer centers in bench-to-bedside
translation, the university identified the need to establish
translational research competencies and capabilities.
Pharmaceutical industry veterans were recruited to es-
tablish best practices. In addition to working with the
University of Kansas cancer biologists, efforts to estab-
lish partnerships with industry, academia, government,
and disease philanthropy collaborators were initiated to
gain access to novel drug targets.
The university has refined its role in cancer therapeu-
tics. With a focus on unmet medical needs such as rare
and neglected diseases and pediatrics, it has established
translational research processes to discover and develop
novel drugs as well as identify new uses for approved
and abandoned drugs. It has integrated and even rebuilt
core facilities, developed a strategy for handling technol-
ogy transfer, put proof-of-concept funding strategies in
place, and formed multidisciplinary and multi-
organizational teams managed by industry-experienced
project managers. The center also invested heavily in
project managers who oversee all aspects of translation,
freeing up investigators to focus on the science, and it is
looking beyond its own walls for promising ideas to
move drug development forward.
By demonstrating successes in translational research,
the university was able to attract top-notch cancer
researchers who are interested in drug discovery and de-
velopment. It has recruited more than 230 years of
pharmaceutical experience over the past five years, from
investigators pursuing target validation to those doing
clinical testing. Its collaborations have brought in a
broad array of new funding sources to support additional
collaborations, including those involving government
and philanthropic organizations and those related to
state economic development initiatives. The center
brought three new therapies to the clinic in 2009, moved
one forward in 2010, and brought five more to the clinic
in 2011.
In sum, institutions benefit from fostering translational
research programs by:
 Connecting their investigators to resources and
collaborators and facilitating affordable access to
expensive shared equipment and facilities.
 Providing unique training opportunities for
undergraduates, graduate students, and
postdoctorates and encouraging new talent to enter
biomedical research.
 Promoting the development of new drugs, devices,
and other medical interventions, which advances
their biomedical research missions, attracts patients,
and enhances their status.
 Gaining access to new funding streams supporting
both institutional and individual projects.
 Attracting public-private partnerships and leveraging
federal and nonfederal resources.
Challenges to engaging basic scientists in translational
research
Meeting participants noted that numerous challenges
can discourage or prevent basic investigators from par-
ticipating in translational science. These include differ-
ences in culture and mindset between basic and clinical
researchers, insufficient and/or nonsupportive infra-
structure, difficulty developing and sustaining collabora-
tions, inadequate training, insufficient funding, and lack
of other incentives and rewards.
Culture and mindset
Basic scientists may see their controlled, hypothesis-driven
research as more rigorous than the goal-directed or de-
scriptive research often conducted with humans in clinical
research settings. On the other hand, clinical scientists may
view their work as superior insofar as it has greater rele-
vance to human health and disease. These perceived differ-
ences not only inhibit collaborations between the two
groups, but also they may discourage basic investigators
from pursuing translational projects (see Table 2). Even
when basic scientists are open to translation, they do not
necessarily speak the same language as their clinical investi-
gator counterparts because of differences in training and
experience.
Noting that she comes from a family of clinical physi-
cians, F. Nina Papavasiliou, Associate Professor and Head
of the Laboratory of Lymphocyte Biology, The Rockefeller
University, stated that “There has been, always, a little bit
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of a mistrust from my end [as] the basic scientist. I always
felt that clinical research was either not rigorous enough
or boring. And my parents and siblings always felt that
basic research was not really useful to them when they
would see, maybe, the outcome of it in their practice 10,
20, or 30 years later—if they’re lucky.”
Institutions where translational research flourishes
have had to focus on overcoming the cultural differences
between basic and clinical scientists. They do this by
creating opportunities for these investigators to share
perspectives, see the value in each other’s work, and em-
brace both hypothesis testing and goal-oriented research.
Philip Haydon, PhD, Professor and Chair, Department of
Neuroscience, Tufts University School of Medicine, said
he was brought to Tufts to change the culture. When he
moved into the university’s neuroscience department,
there was a focus on synaptic physiology, but very little
of the work had any translational thrust. He was faced
with the challenge of identifying translational opportun-
ities for faculty engaged in rigorous, basic work and
helping to move them along that path.
One way Haydon is trying to do this is by developing
three faculty clusters that act much like magnets. These
clusters (in epilepsy, depression, and neurodegeneration)
are open to trainees, as well as faculty, and they meet
every two to three weeks for lunch to hear talks about
their work or discuss a particular topic. As a result, people
who had no interest in diseases are now gaining interest.
Haydon has observed that faculty members who are sur-
rounded by others with a translational focus are more
likely to develop the interests and skills needed to adapt.
Indeed, Papavasiliou noted that having a clinical fellow in
her laboratory “provided a little dose of humility on both
ends and fostered the idea that we can, in fact, both make
an impact quickly while learning from clinical studies.
From our clinical samples, we’ve learned a lot about tran-
scriptome editing that we probably wouldn’t have trusted
had it come from mouse studies alone.”
Insufficient infrastructure to develop clinical protocols,
facilitate exchanges, and enable handoffs
Many basic scientists (and some clinical scientists) find
the pathway to clinical application filled with unfamiliar
requirements and administrative procedures. Transla-
tional research involving human subjects may require
IRB and Privacy Board approval, reporting to data safety
monitoring boards, clinical trials registration, and specia-
lized patient recruitment techniques. Working with in-
dustry adds a level of complexity, because conflict of
interest disclosures and data use and intellectual prop-
erty agreements must be drafted. As a result, carrying
out a clinical protocol can require more steps and time
than a laboratory-based protocol. Basic investigators
usually do not have experience navigating these require-
ments, and their universities may or not have the expert-
ise and infrastructure to help them.
Some institutions have been proactive in addressing
these needs. The Institute for Advancing Medical
Innovation at the University of Kansas Cancer Center
forms project management teams around technologies
ripe for translation. These teams provide investigators with
the expertise they need in areas such as drug discovery
and development, industrial and philanthropic partnering,
technology transfer, and medicinal chemistry. This support
ensures that investigators can focus on their area of ex-
pertise: the science.
Rockefeller also has developed support systems for
translational investigators: it facilitates the development
Table 2 Going It Alone—Sometimes the Translational Scientist Is His or Her Own Best Ally
Daria Mochly-Rosen, PhD, Professor and Senior Associate Dean for
Research and Director of SPARK, Stanford University’s Translational
Research Program, is a protein chemist conducting translational research.
Early in her career, she designed rational inhibitors that could turn off
heart cell enzymes one at a time and discovered enzymes that could
change the rate at which heart cells in culture beat. She thought this
was an important finding that would be of interest to the heart research
community, but when she presented her work at a scientific meeting,
she found the audience to be disinterested in heart rate regulation.
Clinicians, she had been told, already had ways of managing heart rate;
they were concerned with problems such as cardiac ischemia.
When she brought her idea directly to industry, company after company
turned her away. She later realized that there were good reasons for
this: while her work was attractive from a basic research point of view,
the barriers to executing it in patients were huge, and many steps had
to be completed before reaching that goal. Mochly-Rosen reached out
to her colleagues for assistance, but rather than finding support, she was
discouraged from pursuing this line of inquiry and from working with
industry. Translational research, she was told, is not intellectually
challenging, worthwhile, or good for her career. “Career progress in
academia is measured by how many papers are published and how
much grant funding is received rather than, for example, attempting to
produce a new drug,” she said.
Following the advice of a colleague, she invited into her laboratory a
physician who wanted to learn basic research and from whom she
could learn how to study more clinically relevant problems. Her work
eventually led to the discovery of an inhibitor that when administered
after a heart attack dramatically reduces heart damage by 70 percent
and prevents subsequent heart failure, a finding that was demonstrated
in mice, rats, guinea pigs, rabbits, and pigs. Patents were written and the
results published. Yet no one was interested in her findings. Why would
this not be useful in patients, she thought?
But she persevered, formed her own company, KAI Pharmaceuticals, and
spent a year as its Chief Scientific Officer. She helped write an
Investigational New Drug Application and launched a clinical trial.
“Unlike my training in academia, where questions led to the research, in
industry I learned to think about the final product and work backwards,
to identify what research needs to support such a product,” said
Mochly-Rosen. The process was humbling, but also gratifying. “There is
nothing more rewarding than [treating] the first patient. . .or when the
trial is finished, looking at the data. It’s really a true manifestation of
what basic research should eventually lead to.”
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of clinical protocols by providing expertise in the protec-
tion of human subjects, subject recruitment, compliance
with trial registration, and protocol monitoring and
auditing, among other areas. The institution employs re-
search nurses trained in care delivery, and medical
personnel are available to participate in protocols led by
a PhD. Clinical research coordinators, who play critical
roles in regulatory compliance and data integrity, are
also available to any scientist who needs them, as is a
customized, comprehensive information technology plat-
form that allows for conducting protocols.
Rice University is developing a researcher’s toolbox—a
website where everything that is needed to embark on
translational research projects can be found. For example,
to make it easier for investigators to collaborate, Rice is
creating templates for drafting research agreements, estab-
lishing protocols for sharing IRBs, and developing animal
care protocols that would allow the movement of experi-
mental subjects and materials between performance sites.
It also is working with area biotechnology companies to
build a translational and commercial component into the
toolbox. These support systems are critical for helping
basic scientists move their discoveries through the transla-
tional research pipeline to commercialization.
Developing, establishing, and sustaining collaborative
research
A successful translational research environment requires
many different people, trained across many disciplines,
working within a structure that promotes interaction be-
tween those who have clinical understanding of human
health and disease and those who have training and ex-
pertise in fundamental biology, the molecular mechan-
isms of disease, and the use of animal models. “To solve
many of the biggest challenges in health care,” said Gail
Cassell, PhD, Visiting Professor, Department of Global
Health and Social Medicine, Harvard Medical School,
and Vice President of TB Drug Discovery, Infectious
Disease Research Institute in Seattle, “It is absolutely
essential. . .that we have basic scientists working along
with the clinical scientists. And it is essential that we
have the public and the private sectors working together
from the very outset.” Establishing these collaborations is
challenging, however. Academic departments tend to op-
erate in silos, and basic scientists might not even work on
the same campus as clinical researchers, limiting interac-
tions that might spark translational research projects and
making it difficult to obtain assistance and mentorship. It
can be even more difficult for academic and government
researchers to forge relationships with industry partners,
because concerns about perceived or real conflicts of
interest can have a chilling effect on collaborations.
Funding organizations and institutions have been work-
ing to bring basic and clinical—and academic and
industrial scientists—together through investments in
translational research resources and infrastructure. NIH’s
CTSA program has been an important driver in encour-
aging institutions to foster these collaborations, and insti-
tutions are experimenting with a variety of approaches.
The University of California, San Francisco, for example,
is trying to minimize geographic distances between aca-
demic and industrial researchers by co-locating their la-
boratory space as it did in a recently forged partnership
with Pfizer. Ensuring that core resources are available
across departments is another strategy. Providing access
to statistical centers, biorepositories, or datasets, for ex-
ample, can foster cross-fertilization. Institutions have
started mentoring programs through which basic scien-
tists mentor clinical researchers or vice versa, while others
have convened networking events and regular seminars or
workshops that bring diverse disciplines together. Some
academic medical centers have begun asking basic scien-
tists to give presentations during grand rounds. The key
to creating an environment that facilitates collaboration is
to increase exposure to the other research cultures
through closer proximity. Cassell also noted that investi-
gators who have an idea that they want to translate
“should engage industry partners as soon as possible in
the process. All too often, investigators, whether they are
in government or in academia, will wait until they have a
solidified plan, a strategy, and then go seek funding from
the industrial partner. Another equally important mistake
is that industry is looked upon as only potential funders
and not scientific collaborators. The most value industry
can offer is unique expertise.”
Training basic investigators in translational research
There always have been basic scientists who are adept at
transforming their research discoveries into clinical
advances. But as the pressure to accelerate the pace of
translation builds, so does the need for a cadre of basic
investigators with the motivation and skills to apply their
work directly to the improvement of human health.
According to Coller, there are three skills that transla-
tional investigators must learn. The first is the ability to
define a health need with the same precision as a basic
science hypothesis. The second is to understand how to
develop an inexpensive, robust, high-throughput assay
applicable to humans. The third skill is to be able to
conceptualize a pathway to regulatory approval or clin-
ical adoption. Although significant strides have been
made in developing translational research training pro-
grams that teach these and other relevant skills, inad-
equate experiential and didactic training remain a
barrier for many basic investigators.
Whereas clinical examples are integrated into the basic
science coursework many medical students are required
to take, graduate students in basic research programs
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typically are not exposed to clinical cases. Furthermore,
doctoral students often do not receive instruction in
pathobiology and pathophysiology, which are key to
understanding the mechanisms of disease and the dis-
ease relevance of their work. Indeed, Farach-Carson of
Rice University noted that graduate students have less
contact with basic concepts of medicine than in the past.
Another participant noted that “trainees frequently are
more knowledgeable about molecules and structural
biology than about the systems in which they function.”
These limitations, combined with little to no opportun-
ity to interact with clinical researchers or patient popula-
tions, mean that many basic scientists may not think
about the science that they do in the context of human
health and disease, and they may not appreciate the un-
met clinical needs or the clinical context in which poten-
tial interventions would operate. In addition, depending
on an investigator’s area of interest and his or her par-
ticular research, there may be a need to develop familiar-
ity with topics that are not generally covered in basic
science training programs. These may include an under-
standing of disciplines such as biostatistics, pharmacol-
ogy and toxicology, biomedical informatics, clinical
research design, and regulatory processes.
The structure of basic research training at some insti-
tutions may itself present a barrier to acquiring the
requisite knowledge and skills. Translational research is
best conducted by interdisciplinary research teams. Basic
biomedical science graduate students, however, typically
choose a discipline, a department, and even a research
topic early in their education. They generally are trained
on research grants that support the work of a small area
of biology, and their training is designed to prepare
them for a career in individual investigator-initiated re-
search in a very narrow field. Thus, not only may the
concept of team-based, interdisciplinary research feel
foreign to them, but also they may not have the training
to pursue such collaborations successfully.
Narrowly focused training is not unique to basic inves-
tigators. While basic science education may not prepare
trainees to pursue the medical applications of their dis-
coveries, medical education tends not to require suffi-
cient competency in basic science research to allow the
physician to recognize or facilitate the application of sci-
entific discoveries to medical or public health practice.
One panelist noted that medical students typically are
not told how they can be a part of the discovery process.
Communication and collaboration among basic investi-
gators, physician-scientists, and clinical practitioners are
key to advancing translation, and more should be done
to bridge this gap during training.
Biomedical research funding organizations recognize
that this divide exists, and some have stepped in to help
close it. HHMI’s Med into Grad initiative supports and
encourages graduate schools to integrate medical know-
ledge into their doctoral training. The program’s goal is
to produce researchers who will recognize which bio-
logical problems are of the greatest clinical relevance,
have the knowledge and skills necessary to facilitate the
translation of new biological knowledge into tools to im-
prove human health, and be able to create fruitful re-
search partnerships with physicians. To do this, HHMI
has awarded 36 four-year grants totaling $26 million to
institutions offering a doctoral degree in basic biomed-
ical sciences. These awards have been used to enhance
existing graduate programs and initiate new ones.
Recognizing that there are multiple ways to achieve its
goal, HHMI has allowed institutions the flexibility to de-
cide what educational components to include and how
their programs will be structured. For example, Mary
Estes, PhD, Professor, Department of Molecular Virology
and Microbiology, Baylor College of Medicine, described
how her institution has put its Med into Grad award to
use. Baylor’s Translational Biology and Molecular Medi-
cine Graduate program provides doctoral students with
rigorous training in the basic biomedical sciences that
prepares them for participation in clinical and transla-
tional research. Course work includes genetics, human
physiology, immunology, molecular methods, method
and logic of translational research, cellular and molecu-
lar biology of disease, gene regulation, animal models,
pathophysiology, biostatistics for translational research,
ethics, conduct and practical aspects of clinical research,
and a bench-to-beside journal club. In the second year,
students embark on their thesis research and begin clin-
ical project training targeted at specific areas, including
cancer, digestive system disorders, infectious disease,
and reproductive disorders. They also receive dual men-
torship by a basic scientist and a clinical scientist
throughout their graduate training. The clinical mentor
interacts with students in clinics, inpatient hospital
rounds, and medical or research conferences where stu-
dents observe clinical care and observe or participate in
clinical research. The clinical mentor also is a member
of the thesis committee and in many cases helps design
a translational aim of the student’s research project. This
program, like many others sponsored by HHMI, trains
PhDs to be effective translational researchers and has
forged numerous collaborations between participating
PhD and MD faculty.
NIH’s CTSA program also is beginning to shape trans-
lational research training of basic biomedical science
investigators. Institutions receiving CTSA funding are
expected to provide research, education, training, and
career development in clinical and translational sciences.
With funding from the program, The Rockefeller Uni-
versity initiated a master’s program in clinical and trans-
lational science. It also has developed a one-year
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certificate program to provide basic science trainees with
an introduction to the principles and practice of clinical
and translational research and the opportunity to de-
velop a translational research protocol. In addition to
developing their own training programs, CTSA institu-
tions have been working together to develop best prac-
tices for clinical and translational research training. For
instance, the CTSA consortium created a set of core
competencies that includes 14 thematic areas that
should shape the training experiences of junior investi-
gators. The competencies define the skills, attributes,
and knowledge needed for this type of research and can
serve as a guide for anyone considering the development
of a translational curriculum at multiple graduate levels.
Although national award competitions have catalyzed
the establishment of training programs, some institu-
tions, recognizing the value of translational science, have
embarked on their own initiatives. The MD Anderson
Cancer Center’s Translational Research in Multi-Discip-
linary Program (TRIUMPH), for example, is unique in
its focus on training postdoctoral- level scientists.
In addition to providing training at the graduate and
postgraduate level, some meeting participants suggested
that it may be useful to open the possibilities of transla-
tional research to undergraduates and even high school
students. This may present a unique opportunity, because
students at these levels might more readily embrace trans-
lational research as a career path, not yet having formed
narrower conceptions of their future careers. Baylor, for
example, offers a summer program for undergraduates, in
which students may work in translational research. Estes
pointed out that several of the students in its Translational
Biology and Molecular Medicine Graduate Program ini-
tially were exposed to translational science through that
program. Similar programs for undergraduate students
have been established at MD Anderson Cancer Center
and The Ohio State University.
Availability and types of funding
Many of the translational research success stories
described during the meeting had one thing in com-
mon—a component that involved the creative piecing
together of resources from many places. Despite national
efforts to encourage translational science, some meeting
participants lamented the lack of support for individual
investigator-initiated projects in this area. And, while
making a move to translational research can open up new
funding streams for some basic scientists, others find them-
selves at a disadvantage in applying for grants to support
that work. They note that study sections do not always have
the expertise appropriate for reviewing translational proto-
cols. Reviewers may not appreciate the merits of applied or
translational work, and they may be more sensitive to the
strengths of basic, hypothesis-driven proposals. Moreover,
investigators who are able to acquire funding note that it is
often insufficient to cover the full cost of a project. At least
one presenter reported that he had to siphon money away
from existing projects to support this work.
Mechanisms of support for trainees may not be opti-
mal for encouraging the pursuit of translational research
projects. Although there are programs designed to pro-
vide training in translation, as described earlier, these
opportunities are limited. The vast majority of postdoc-
toral fellows supported by NIH are funded through indi-
vidual investigator-initiated grants, and they are required
to focus on the research for which the grant was
awarded. This limits opportunities to expand their pro-
jects into the translational space or to work on collab-
orative projects that may ultimately spark new research
directions. It also may create a certain amount of tunnel
vision with regard to their research interests.
Research funders have taken different approaches to
supporting the participation of basic scientists in transla-
tional research. In addition to its investigator-initiated
research grant mechanisms, NIH provides funding
through targeted programs to encourage research in spe-
cific areas of translation. Its CTSA program, while not
providing direct support to scientists, has catalyzed insti-
tutional efforts to engage and support basic investigators
and trainees. The agency also has mechanisms to pro-
vide investigators with access to translational research
resources and equipment. The U.S. Department of
Veterans Affairs has a small intramural research pro-
gram. Although about 60 percent of its investigators are
clinicians, it supports a fair number of basic investiga-
tors and has the flexibility to convene teams of basic and
clinical scientists around translational research projects.
Private support is more limited, but it does exist. Some
foundations support basic investigators conducting funda-
mental research in areas relevant to a disease for which
they want to provide research funding. Other organiza-
tions are less interested in funding a particular project
than they are an investigator who is likely to make an im-
pact. HHMI’s investigator program, for example, focuses
on “people not projects,” said Dennis McKearin, PhD,
HHMI Senior Scientific Officer. “By giving basic investiga-
tors flexible budgets large enough to explore new areas
[and] with low administrative burdens,” they have the abil-
ity to move good ideas from the bench to the bedside. Par-
ticipants generally agreed that a diversity of approaches,
including support for infrastructure and investigators and
for targeted and open-ended research, would be important
to engaging basic investigators and advancing bench-to-
bedside translation.
Lack of recognition and incentives
Academic tenure and promotion policies are one area in
which incentives may not be optimal for encouraging
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basic investigators to develop a translational research
program. Tenure-track faculty are required to bring in
research funding and make an identifiable intellectual
contribution to their fields to gain tenure and promo-
tions, and these contributions are usually measured in
research grants and publications. Moving a discovery
through the translational research pipeline often involves
team science that may require as many as 30 or 40 colla-
borators. Tenure, promotion, and appointment committees
are challenged to evaluate the importance and impact of
the individual contribution a single faculty member makes
in the context of a multi-investigator translational project.
The existing paradigms used to evaluate basic science
faculty, including numbers of grants and publications, are
not always sufficient to capture the merits of faculty con-
tributions to the translational research enterprise.
Tenure and promotion committees also may undervalue
the contributions of scientists who bring technological ex-
pertise to collaborations—such as mass spectrometry
experts—even if that technology was key to the experi-
ments and resulting publications. Moreover, compared to
basic science studies, it often takes longer to bring clinical
and translational research projects to fruition, resulting in
a longer duration between publications, which may disad-
vantage faculty during their evaluations. This problem is
magnified by a lack of understanding of translational sci-
ence that can prevail among multicollegiate faculty serving
on tenure committees in university senates when clear
guidelines for evaluating collaborative and/or translational
research are absent or marginalized. Recognizing the shift
toward team-based, interdisciplinary, translational science,
some institutions have started to explore changes in their
tenure and promotions policies and processes to ensure
that investigators are recognized for their research
contributions.
Adding to these difficulties are challenges scientists face
in publishing their translational work. Like study sections
and basic science promotion committees, editorial boards
and reviewers may place a higher value on hypothesis-
driven basic science, making it difficult to publish transla-
tional research. Moreover, journals may not have a mech-
anism to acknowledge the contributions that each
member of a research team makes to the published work.
Although journals devoted to translational research may
address these concerns, only a few of them exist.
Many of the concerns cited by meeting participants
were echoed by respondents to FASEB’s translational re-
search survey. More than 50 percent of survey respon-
dents found it difficult to obtain sufficient funding for
translational research, navigate human subjects protections
regulations, obtain the skills necessary for developing drugs
and devices, and access clinical samples. Obtaining didactic
and experiential training, being recognized for team-based
research, earning tenure and promotions, as well as
communicating across disciplines and identifying collabora-
tors also were cited by many respondents as being difficult.
The survey also revealed that translational investigators
found it less difficult to overcome certain barriers than
respondents who had not participated in translational re-
search perceived it to be. Compared to respondents with-
out translational research experience, translational
investigators found it less difficult to obtain clinical sam-
ples and other necessary resources; obtain guidance, men-
torship, skills, and training; identify collaborators; and
identify the health relevance of their research. It may be
that establishing a translational research program is less
difficult than investigators perceive it to be or that those
who encounter difficulties ultimately decide not to pursue
this line of inquiry. Whatever the explanation, reducing
the barriers will likely encourage more basic scientists to
explore the translational potential of their work.
Recommendations
There is much that investigators, institutions, profes-
sional societies, publishers, and funding institutions can
do to support and facilitate the involvement of basic
scientists in translational research: creating more train-
ing opportunities, reforming recognition and reward pol-
icies, fostering collaborations, and providing diverse and
flexible forms of financial support will help. (See Add-
itional file 5 for a list of resources.) But in addition to
creating optimal research and training environments, we
must ensure that there are basic investigators who want
to pursue translational science. The research community
should explore ways to spark interest in translation
among trainees and established investigators who may
not have considered how they could apply their own
interest and expertise in basic biological science to meet
public health needs. All of these efforts will require leaders
who are willing to take risks, create new funding models
and reward systems, and provide enhanced environments
for science education, training, and collaboration.
Overarching recommendations
 Funding agencies should continue to support basic
science and ensure a deep and broad reservoir of
new knowledge from which translational research
can flourish.
 Additional funding should be provided for both
individual and team-based investigator-initiated
translational research grants, beyond the support for
translational research infrastructure currently available.
 Institutions, scientific publishers, professional
societies, and individual scientists should encourage
and facilitate a “cultural shift” toward greater
collaboration, cooperation, communication, and
respect among basic and clinical scientists. The
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unique roles of both clinical and basic scientists in
translational research must be valued and their
contributions to each other’s research programs
recognized, and this commensal approach must be
modeled for the next generation of scientists.
 Institutions should examine promotion and tenure
processes to ensure that the expectations of basic
and clinical scientists engaged in translational
research are clearly articulated and that their
research contributions are quantified, evaluated, and
recognized relative to the established expectations
 Institutions and professional societies should provide
environments and opportunities that facilitate
interactions between basic and clinical researchers
to spark collaborative activities that will expedite the
translation of discoveries to application.
Recommendations to promote interest, education, and
training in translational science
The first steps in facilitating the participation of basic
scientists in translational research are to spark their inter-
est in advancing the health applications of their work and
help them cultivate their ability to do so. High school and
undergraduate students should be made aware of potential
career paths in translation, interested graduate and post-
doctoral scientists should be engaged early in their
careers, and all investigators should have opportunities to
acquire relevant experiential and didactic training.
It is recommended that institutions:
 Provide didactic coursework, case-based learning,
and seminars that cover a variety of disease topics
and clinical issues.
 Incorporate pathobiology and pathophysiology
courses into basic science training programs—fields
that are especially important foundations for
understanding human health and disease processes.
 Provide opportunities and release time for basic
scientists and trainees to acquire clinical experiences
that will help put basic research in context. This can
include opportunities for basic scientists to
participate in ward rounds; attend clinics; observe
clinical procedures, autopsies, and surgeries; and/or
take minisabbaticals to acquire extended training in
and understanding of the experimental paradigms
possible in humans.
 Facilitate training in the wide range of disciplines
and skills needed to conduct translational research
effectively.
It is recommended that professional societies:
 Explore a variety of approaches to spark interest,
education, and training in translational research
through professional meetings and other activities,
including:
 Highlighting translational research at meetings by
calling out these sessions in meeting materials or
creating a translational research track for poster
presentations and talks.
 Establishing networking opportunities for basic
and clinical investigators and trainees with similar
research interests.
 Offering workshops that provide basic and
clinical scientists and trainees with perspectives
on translational research and practical tools for
establishing translational research programs.
 Providing information about translational
research training and career opportunities to
students at scientific meetings, including student-
oriented meetings.
It is recommended that funding organizations:
 Establish and evaluate translational research training
mechanisms for basic investigators and trainees.
 Encourage and support the mentoring of basic
scientists and trainees in translational research,
including mentoring by clinical and translational
scientists and by clinicians.
It is recommended that individual scientists:
 Learn to define a health problem with the same
precision as a basic science hypothesis.
 Actively seek and be open to the perspectives of
scientists from different disciplines.
 Seek opportunities and funding to acquire
translational research training and mentorship,
including through course work, seminars, and
workshops; rotations in or collaborations with
clinical research laboratories; and participation in
clinical experiences.
It is recommended that institutions, funding organiza-
tions, and professional societies work together to:
 Establish and/or facilitate the establishment of
summer research experiences for high school and
undergraduate students that provide exposure to
translational research.
Recommendations to promote access to translational
research collaborators and resources
If basic investigators are to play a meaningful role in
translating their discoveries into health applications, then
they must have opportunities to interact with clinical
investigators, clinicians, and industry partners as well as
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investigators from other disciplines. They also need access
to the tools and resources necessary to conduct transla-
tional science.
It is recommended that institutions, funders, and pro-
fessional societies:
 Facilitate interaction and collaboration among basic
and clinical scientists and clinicians across sectors
and disciplines, including among researchers in the
life and physical sciences and mathematics through
a variety of approaches, including:
 Creating training and funding mechanisms that
encourage interdisciplinary or multisector
partnerships.
 Establishing or supporting seminars and workshops
as well as networking opportunities (e.g., research
“speed dating”) that bring scientists and clinicians
from different disciplines and sectors together.
 Creating databases that facilitate the
identification of potential collaborators.
 Facilitate access to the research and development
resources and tools that basic scientists need to
conduct translational research. For example,
 Institutions and funders should support
centers or programs that provide translational
research services, including clinical support
and expertise in developing technology
transfer and data sharing agreements, writing
IRB protocols, recruiting patients, and
executing clinical trials.
 Professional societies should publicize the
availability of national resources and funding
opportunities and provide training and
information to help members compete
successfully for these opportunities.
Recommendations to recognize and reward translational
scientists
Incentives are needed to encourage and support basic
scientists interested in pursuing translational research. In-
stitutional retention, promotion, and tenure policies and
publishing policies should be modified to ensure that
investigators are recognized and rewarded for the contri-
butions that they make to translational science.
It is recommended that institutions:
 Enable investigators to contribute to basic, clinical,
and translational science and recognize that
evaluation in different areas may require enlisting
the expertise of faculty from other than the
investigator’s primary department.
 Ensure that promotion and tenure guidelines are
clear with regard to how investigators will be
evaluated for contributions they make to
interdisciplinary and team research.
 Carefully consider the composition of tenure review
committees so that nontraditional—but still
rigorous—scholarship is recognized.
 Consider extending the tenure clock to
accommodate scientists involved in translational
studies involving human subjects, which often take
longer to complete and publish than studies that do
not involve human subjects.
 Consider the impact of a basic investigator’s
work, not just the quality or quantity of
publications, when evaluating his or her
publication records.
It is recommended that scientific publishers and editors:
 Ensure that the roles of authors are clearly
articulated in publications.
 Highlight the potential contributions of basic
research findings to public health by publishing
articles or editorials that illustrate the
implications a particular finding has for
translation.
 Encourage high-impact journals to embrace
translational studies (with the caveat that there is
still a need for specialty journals that focus on
translational research).
It is recommended that individual scientists:
 Be aware of tenure expectations, clearly articulate
their career goals, and negotiate department
concurrence. They should define the intellectual
space or spaces in which they are going to be
leaders, especially if translational science is to be
important in achieving tenure.
 Seek reviewers who understand and value the
contributions they make to translational research
when soliciting tenure review letters.
Recommendations for funding organizations
Public and private funders of biomedical research play a
key role in encouraging the entry of basic scientists into
translational research. Funders provide direct research
support, access to research resources and equipment,
and support for the development of training programs.
Funding policies and incentives also can motivate the in-
stitutional changes needed to support basic investigators.
Together, organizations that support translational re-
search have a wealth of information about the efficacy of
various programs and policies that could be used to
optimize the enterprise going forward.
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To attract basic scientists to translational research, it
is recommended that funding agencies:
 Recognize milestone and outcome-driven projects as
well as those aimed at open-ended inquiry when
making funding decisions.
 Fund translational research projects that engage
investigators across disciplines.
 Provide supplements to basic research grants that
allow investigators to extend basic research findings
into the translational research domain. Similarly,
provide supplements to clinical investigators to
conduct laboratory work based on clinical findings.
 Provide sustained support for translational research
infrastructure, commercialization centers, and
research training programs.
 Sponsor meetings and other activities to bring
groups of researchers together to interact and learn
from one another.
 Evaluate the outcomes of translational research
programs/mechanisms across the enterprise to
identify and replicate the programs that are working.
 Fund access to core facilities and other resources
and advertise these resources to the basic science
community.
 Ensure that grant application review panels have the
appropriate expertise to review translational
research projects fairly. This may include creating
separate translational research review groups or
study sections and/or ensuring that translational
researchers are among the scientists represented in
review groups.
Conclusion
Basic science is the foundation of medical advancement.
Investigators with a deep understanding of fundamental
biology and the mechanisms of disease are essential for
translating laboratory discoveries into new and improved
health interventions, diagnostics, and treatments. Add-
itional training, resources, and support would enable basic
scientists to move their discoveries forward effectively and
efficiently. Although significant strides have been made,
more can be done to optimize basic scientists’ participa-
tion in translational research. The research community
should expand translational research training opportun-
ities for basic researchers and trainees; facilitate their ac-
cess to the funding, equipment, infrastructure, and other
resources needed for translation; encourage and support
collaboration between basic and clinical investigators
across research disciplines and sectors; and recognize and
reward basic scientists for the contributions that they
make to this growing field. Implementing these recom-
mendations will require action by research institutions and
funders, scientific publishers, professional societies, and
investigators themselves. Scientific societies such as FASEB
and the many disciplinary societies representing biomed-
ical researchers have a special role to play in advocating
for these changes. We hope that this report will serve as a
starting point for moving forward on this important issue.
Endnotes
aNational Institutes of Health. 2009. “NIH Announces
New Program to Develop Therapeutics for Rare and
Neglected Diseases.” Accessed May 30, 2011, at www.
nih.gov/news/health/may2009/nhgri-20.htm.
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